$EYPT
EyePoint Pharmaceuticals, Inc.

2016 Q3 Form 10-K Financial Statement

#000119312516708358 Filed on September 13, 2016

View on sec.gov

Income Statement

Concept 2016 Q3 2015 Q2 2015 Q1
Revenue $277.0K $409.0K $328.0K
YoY Change -40.56% 40.07% -83.53%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.290M $2.410M $2.040M
YoY Change 67.01% 20.5% 4.62%
% of Gross Profit
Research & Development $4.178M $3.200M $3.339M
YoY Change 19.99% 38.53% 47.16%
% of Gross Profit
Depreciation & Amortization $6.000K $220.0K $210.0K
YoY Change -79.31% -8.33% -4.55%
% of Gross Profit
Operating Expenses $7.463M $5.610M $5.380M
YoY Change 36.94% 30.47% 27.76%
Operating Profit -$7.186M -$5.200M -$5.052M
YoY Change 44.18% 29.61% 127.67%
Interest Expense $20.00K $10.00K $10.00K
YoY Change 100.0%
% of Operating Profit
Other Income/Expense, Net $24.00K $0.00 $10.00K
YoY Change 140.0% 900.0%
Pretax Income -$7.162M -$5.190M -$5.042M
YoY Change 43.99% 29.43% 127.32%
Income Tax $0.00 -$50.00K -$44.00K
% Of Pretax Income
Net Earnings -$7.162M -$5.146M -$4.998M
YoY Change 45.19% 29.72% 128.53%
Net Earnings / Revenue -2585.56% -1258.19% -1523.78%
Basic Earnings Per Share -$0.17 -$0.17
Diluted Earnings Per Share -$2.094M -$0.17 -$0.17
COMMON SHARES
Basic Shares Outstanding 34.18M shares 29.41M shares 29.41M shares
Diluted Shares Outstanding 29.41M shares 29.41M shares

Balance Sheet

Concept 2016 Q3 2015 Q2 2015 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $22.50M $28.50M $31.70M
YoY Change -6.25% 55.74% 48.83%
Cash & Equivalents $14.31M $19.12M $23.01M
Short-Term Investments $8.200M $9.400M $8.700M
Other Short-Term Assets $500.0K $700.0K $1.000M
YoY Change -16.67% 40.0% 66.67%
Inventory
Prepaid Expenses
Receivables $500.0K $600.0K $400.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $23.50M $29.84M $33.08M
YoY Change -6.6% 54.27% 47.26%
LONG-TERM ASSETS
Property, Plant & Equipment $257.0K $338.0K $280.0K
YoY Change -19.18% 13.8% -4.11%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $300.0K $300.0K $300.0K
YoY Change 0.0% 0.0% 0.0%
Total Long-Term Assets $1.430M $2.529M $2.625M
YoY Change -37.74% -24.03% -26.24%
TOTAL ASSETS
Total Short-Term Assets $23.50M $29.84M $33.08M
Total Long-Term Assets $1.430M $2.529M $2.625M
Total Assets $24.93M $32.37M $35.70M
YoY Change -9.2% 42.77% 37.2%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.015M $744.0K $812.0K
YoY Change 13.66% 60.34% 6.7%
Accrued Expenses $3.688M $2.571M $1.371M
YoY Change 78.42% 68.7% 13.97%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $4.842M $3.348M $2.218M
YoY Change 61.78% 57.48% -2.55%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $5.600M $5.700M $5.600M
YoY Change 0.0% 1.79% 3.7%
Total Long-Term Liabilities $5.600M $5.700M $5.600M
YoY Change 0.0% 1.79% 3.7%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.842M $3.348M $2.218M
Total Long-Term Liabilities $5.600M $5.700M $5.600M
Total Liabilities $10.49M $8.999M $7.855M
YoY Change 21.4% 16.16% 2.35%
SHAREHOLDERS EQUITY
Retained Earnings -$299.4M -$270.7M -$265.5M
YoY Change 8.63% -2.29% -2.76%
Common Stock $313.0M $293.1M $29.00K
YoY Change 6.64% 0.75% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $14.33M $23.37M $27.85M
YoY Change
Total Liabilities & Shareholders Equity $24.93M $32.37M $35.70M
YoY Change -9.2% 42.77% 37.2%

Cashflow Statement

Concept 2016 Q3 2015 Q2 2015 Q1
OPERATING ACTIVITIES
Net Income -$7.162M -$5.146M -$4.998M
YoY Change 45.19% 29.72% 128.53%
Depreciation, Depletion And Amortization $6.000K $220.0K $210.0K
YoY Change -79.31% -8.33% -4.55%
Cash From Operating Activities -$6.490M -$3.000M -$3.960M
YoY Change 44.54% 7.91% 112.9%
INVESTING ACTIVITIES
Capital Expenditures $0.00 -$90.00K -$40.00K
YoY Change -100.0% -47.06% -33.33%
Acquisitions
YoY Change
Other Investing Activities $5.480M -$790.0K -$2.740M
YoY Change -1114.81% 216.0% 23.98%
Cash From Investing Activities $5.480M -$880.0K -$2.780M
YoY Change -1096.36% 109.52% 23.01%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 10.00K 0.000 0.000
YoY Change 0.0% -100.0% -100.0%
NET CHANGE
Cash From Operating Activities -6.490M -3.000M -3.960M
Cash From Investing Activities 5.480M -880.0K -2.780M
Cash From Financing Activities 10.00K 0.000 0.000
Net Change In Cash -1.000M -3.880M -6.740M
YoY Change -80.12% 20.5% -301.8%
FREE CASH FLOW
Cash From Operating Activities -$6.490M -$3.000M -$3.960M
Capital Expenditures $0.00 -$90.00K -$40.00K
Free Cash Flow -$6.490M -$2.910M -$3.920M
YoY Change 44.19% 11.49% 117.78%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2013Q3 us-gaap Share Price
SharePrice
3.10
CY2016Q1 us-gaap Share Price
SharePrice
4.00
CY2015Q4 dei Entity Public Float
EntityPublicFloat
140134000
CY2016Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
34176999 shares
CY2014Q1 us-gaap Share Price
SharePrice
4.11
CY2013Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6899000
CY2013Q2 us-gaap Stockholders Equity
StockholdersEquity
7700000
CY2014Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15334000
CY2014Q2 us-gaap Stockholders Equity
StockholdersEquity
14924000
CY2014Q2 psdv Warrants Outstanding And Exercisable Weighted Average Exercise Price
WarrantsOutstandingAndExercisableWeightedAverageExercisePrice
3.67
CY2014Q2 psdv Warrants To Purchase Common Shares Outstanding And Exercisable
WarrantsToPurchaseCommonSharesOutstandingAndExercisable
1176105 shares
CY2015Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
735000
CY2015Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015Q2 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
2194000
CY2015Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1806000
CY2015Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2015Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
338000
CY2015Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2144000
CY2015Q2 us-gaap Stockholders Equity
StockholdersEquity
23368000
CY2015Q2 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
3431000
CY2015Q2 us-gaap Assets Fair Value Disclosure Recurring
AssetsFairValueDisclosureRecurring
25249000
CY2015Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
29412365 shares
CY2015Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
29412365 shares
CY2015Q2 us-gaap Assets
Assets
32367000
CY2015Q2 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
55000
CY2015Q2 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2015Q2 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
110000
CY2015Q2 us-gaap Assets Current
AssetsCurrent
29838000
CY2015Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
15835000
CY2015Q2 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
32077000
CY2015Q2 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
640000
CY2015Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000 shares
CY2015Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
293060000
CY2015Q2 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
1246000
CY2015Q2 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
0
CY2015Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
19121000
CY2015Q2 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
622000
CY2015Q2 us-gaap Common Stock Value
CommonStockValue
29000
CY2015Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
5596000
CY2015Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
744000
CY2015Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
33000
CY2015Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
384000
CY2015Q2 us-gaap Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
950000
CY2015Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
945000
CY2015Q2 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
32717000
CY2015Q2 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
25736000
CY2015Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2571000
CY2015Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2015Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2015Q2 us-gaap Other Assets
OtherAssets
116000
CY2015Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2015Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
9414000
CY2015Q2 us-gaap Liabilities
Liabilities
8999000
CY2015Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
32367000
CY2015Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1925000
CY2015Q2 us-gaap Liabilities Current
LiabilitiesCurrent
3348000
CY2015Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
28000
CY2015Q2 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2015Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-270666000
CY2015Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
681000
CY2015Q2 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2015Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2015Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
150000
CY2015Q2 psdv Domestic Federal Tax Benefit From Utilization Of Tax Loss Carry Forwards
DomesticFederalTaxBenefitFromUtilizationOfTaxLossCarryForwards
2500000
CY2015Q2 psdv Warrants Outstanding And Exercisable Weighted Average Exercise Price
WarrantsOutstandingAndExercisableWeightedAverageExercisePrice
3.67
CY2015Q2 psdv Deferred Tax Assets Liabilities Net Before Valuation Allowance
DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance
32077000
CY2015Q2 psdv Accrued Clinical Expense Current
AccruedClinicalExpenseCurrent
1424000
CY2015Q2 psdv Warrants To Purchase Common Shares Outstanding And Exercisable
WarrantsToPurchaseCommonSharesOutstandingAndExercisable
1176105 shares
CY2016Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1314000
CY2016Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q2 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
2000
CY2016Q2 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
2198000
CY2016Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1693000
CY2016Q2 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
4111000
CY2016Q2 us-gaap Assets Fair Value Disclosure Recurring
AssetsFairValueDisclosureRecurring
27535000
CY2016Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
34172919 shares
CY2016Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
34172919 shares
CY2016Q2 us-gaap Assets
Assets
31619000
CY2016Q2 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
60000
CY2016Q2 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2016Q2 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
141000
CY2016Q2 us-gaap Assets Current
AssetsCurrent
29963000
CY2016Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
13856000
CY2016Q2 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
38866000
CY2016Q2 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
367000
CY2016Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000 shares
CY2016Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
1700000
CY2016Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
312208000
CY2016Q2 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
13681000
CY2016Q2 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
1484000
CY2016Q2 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
0
CY2016Q2 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
13679000
CY2016Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15313000
CY2016Q2 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
488000
CY2016Q2 us-gaap Common Stock Value
CommonStockValue
34000
CY2016Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
5585000
CY2016Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1363000
CY2016Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
147000
CY2016Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
535000
CY2016Q2 us-gaap Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
854000
CY2016Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
852000
CY2016Q2 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
39233000
CY2016Q2 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
31299000
CY2016Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3583000
CY2016Q2 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
1227000
CY2016Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2016Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2016Q2 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
0
CY2016Q2 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
0
CY2016Q2 us-gaap Other Assets
OtherAssets
114000
CY2016Q2 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
432000
CY2016Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2016Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
13679000
CY2016Q2 us-gaap Liabilities
Liabilities
10738000
CY2016Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
31619000
CY2016Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1102000
CY2016Q2 us-gaap Liabilities Current
LiabilitiesCurrent
5093000
CY2016Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
56000
CY2016Q2 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
13000000
CY2016Q2 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
364000
CY2016Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2016Q2 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
431000
CY2016Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
290000
CY2016Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1983000
CY2016Q2 us-gaap Stockholders Equity
StockholdersEquity
20881000
CY2016Q2 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2016Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-292213000
CY2016Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
483000
CY2016Q2 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2016Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2016Q2 us-gaap Security Deposit
SecurityDeposit
150000
CY2016Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
150000
CY2016Q2 psdv Cash And Cash Equivalents And Marketable Securities Fair Value
CashAndCashEquivalentsAndMarketableSecuritiesFairValue
29000000
CY2016Q2 psdv Collaboration Agreement Ownership Percentage In Company
CollaborationAgreementOwnershipPercentageInCompany
0.054 pure
CY2016Q2 psdv Estimated Annual Amortization Of Intangible Assets
EstimatedAnnualAmortizationOfIntangibleAssets
735000
CY2016Q2 psdv Warrants Outstanding And Exercisable Weighted Average Exercise Price
WarrantsOutstandingAndExercisableWeightedAverageExercisePrice
2.50
CY2016Q2 psdv Deferred Tax Assets Liabilities Net Before Valuation Allowance
DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance
38866000
CY2016Q2 psdv Accrued Clinical Expense Current
AccruedClinicalExpenseCurrent
1678000
CY2016Q2 psdv Warrants To Purchase Common Shares Outstanding And Exercisable
WarrantsToPurchaseCommonSharesOutstandingAndExercisable
623605 shares
CY2013Q3 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
3494550 shares
CY2013Q3 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
890000
CY2013Q3 psdv Gross Proceeds From Issuance Of Common Stock
GrossProceedsFromIssuanceOfCommonStock
10800000
CY2016Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
4440000 shares
CY2016Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1300000
CY2016Q1 psdv Gross Proceeds From Issuance Of Common Stock
GrossProceedsFromIssuanceOfCommonStock
17800000
CY2014Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
1700000 shares
CY2014Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
191000
CY2014Q1 psdv Number Of Institutional Investors
NumberOfInstitutionalInvestors
1 Investor
CY2014Q1 psdv Gross Proceeds From Issuance Of Common Stock
GrossProceedsFromIssuanceOfCommonStock
7000000
CY2014 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
45000
CY2014 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4967106 shares
CY2014 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1411000
CY2014 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
8435000
CY2014 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-4000
CY2014 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1411000
CY2014 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
-130000
CY2014 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7468000
CY2014 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.49
CY2014 us-gaap Depreciation
Depreciation
139000
CY2014 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.49
CY2014 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-13231000
CY2014 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
778000
CY2014 us-gaap Employee Service Share Based Compensation Cash Received From Exercise Of Stock Options
EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions
987000
CY2014 us-gaap Revenues
Revenues
3473000
CY2014 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
159000
CY2014 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
485000
CY2014 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
5000
CY2014 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-381000
CY2014 us-gaap Income Taxes Paid
IncomeTaxesPaid
0
CY2014 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-4585000
CY2014 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
4619000
CY2014 us-gaap Operating Expenses
OperatingExpenses
16963000
CY2014 us-gaap Net Income Loss
NetIncomeLoss
-13355000
CY2014 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
2964000
CY2014 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-13485000
CY2014 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
66000
CY2014 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
124000
CY2014 us-gaap License And Services Revenue
LicenseAndServicesRevenue
2155000
CY2014 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-11712000
CY2014 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-1773000
CY2014 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-213000
CY2014 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1110000
CY2014 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
124000
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000 pure
CY2014 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9573000
CY2014 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
987000
CY2014 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
18057000
CY2014 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
27443592 shares
CY2014 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
987000
CY2014 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
0 shares
CY2014 us-gaap Operating Income Loss
OperatingIncomeLoss
-13490000
CY2014 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
19044000
CY2014 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
78000
CY2014 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
157000
CY2014 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
169000
CY2014 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-267000
CY2014 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
0
CY2014 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-130000
CY2014 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-10671000
CY2014 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-693000
CY2014 us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
-103000
CY2014 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
248000
CY2014 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
150000
CY2014 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
18057000
CY2014 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
78000
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0199 pure
CY2014 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
27443592 shares
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.96 pure
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
841000
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0170 pure
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.48
CY2014 us-gaap Share Based Compensation
ShareBasedCompensation
1411000
CY2014 us-gaap Royalty Revenue
RoyaltyRevenue
1318000
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.94 pure
CY2014 psdv Proceeds From Maturity Of Marketable Securities
ProceedsFromMaturityOfMarketableSecurities
3350000
CY2014 psdv Income Tax Reconciliation Capital Loss Expirations
IncomeTaxReconciliationCapitalLossExpirations
0
CY2014 psdv Defined Contribution Plan Contributions By Employer
DefinedContributionPlanContributionsByEmployer
189000
CY2014 psdv Income Tax Reconciliation Expiration Of State Net Operating Loss Carry Forwards
IncomeTaxReconciliationExpirationOfStateNetOperatingLossCarryForwards
161000
CY2014 psdv Incremental Common Shares Attributable To Warrants
IncrementalCommonSharesAttributableToWarrants
0 shares
CY2014 psdv Income Tax Reconciliation Permanent Items
IncomeTaxReconciliationPermanentItems
221000
CY2014 psdv Increase Decrease In Deferred Rent
IncreaseDecreaseInDeferredRent
37000
CY2015 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
98000
CY2015 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
263000
CY2015 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2563293 shares
CY2015 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1961000
CY2015 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
3787000
CY2015 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-12000
CY2015 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1961000
CY2015 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
-167000
CY2015 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8056000
CY2015 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.22
CY2015 us-gaap Depreciation
Depreciation
112000
CY2015 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.21
CY2015 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
6248000
CY2015 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
770000
CY2015 us-gaap Employee Service Share Based Compensation Cash Received From Exercise Of Stock Options
EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions
235000
CY2015 us-gaap Revenues
Revenues
26565000
CY2015 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
471000
CY2015 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
494000
CY2015 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
22000
CY2015 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1053000
CY2015 us-gaap Income Taxes Paid
IncomeTaxesPaid
263000
CY2015 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
2191000
CY2015 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-3572000
CY2015 us-gaap Operating Expenses
OperatingExpenses
20144000
CY2015 us-gaap Net Income Loss
NetIncomeLoss
6347000
CY2015 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
10222000
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
6443000
CY2015 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-6733000
CY2015 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-95000
CY2015 us-gaap License And Services Revenue
LicenseAndServicesRevenue
25411000
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
8120000
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-1677000
CY2015 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
292000
CY2015 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
136000
CY2015 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-99000
CY2015 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
956441 shares
CY2015 us-gaap Operating Income Loss
OperatingIncomeLoss
6421000
CY2015 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
235000
CY2015 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0
CY2015 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
137000
CY2015 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
313000
CY2015 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-94000
CY2015 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-4000
CY2015 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
96000
CY2015 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
10297000
CY2015 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
435000
CY2015 us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
124000
CY2015 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
161000
CY2015 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
0
CY2015 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
CY2015 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0200 pure
CY2015 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
30584140 shares
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.93 pure
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000 pure
CY2015 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29378250 shares
CY2015 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
235000
CY2015 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12088000
CY2015 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
235000
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
257000
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0170 pure
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.33
CY2015 us-gaap Share Based Compensation
ShareBasedCompensation
1961000
CY2015 us-gaap Royalty Revenue
RoyaltyRevenue
1154000
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.79 pure
CY2015 psdv Current Federal Tax Expense Before Utilization Of Operating Loss Carryforwards
CurrentFederalTaxExpenseBeforeUtilizationOfOperatingLossCarryforwards
2800000
CY2015 psdv Proceeds From Maturity Of Marketable Securities
ProceedsFromMaturityOfMarketableSecurities
3650000
CY2015 psdv Income Tax Reconciliation Capital Loss Expirations
IncomeTaxReconciliationCapitalLossExpirations
511000
CY2015 psdv Increase Decrease In Deferred Tax Assets Net
IncreaseDecreaseInDeferredTaxAssetsNet
-1100000
CY2015 psdv Defined Contribution Plan Contributions By Employer
DefinedContributionPlanContributionsByEmployer
187000
CY2015 psdv Income Tax Reconciliation Expiration Of State Net Operating Loss Carry Forwards
IncomeTaxReconciliationExpirationOfStateNetOperatingLossCarryForwards
0
CY2015 psdv Warrants To Purchase Common Shares Expired
WarrantsToPurchaseCommonSharesExpired
0 shares
CY2015 psdv Incremental Common Shares Attributable To Warrants
IncrementalCommonSharesAttributableToWarrants
249449 shares
CY2015 psdv Income Tax Reconciliation Permanent Items
IncomeTaxReconciliationPermanentItems
236000
CY2015 psdv Exercise Price Of Expired Warrants
ExercisePriceOfExpiredWarrants
0.00
CY2015 psdv Increase Decrease In Deferred Rent
IncreaseDecreaseInDeferredRent
18000
CY2016 dei Entity Registrant Name
EntityRegistrantName
PSIVIDA CORP.
CY2016 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
87000
CY2016 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5605026 shares
CY2016 dei Document Type
DocumentType
10-K
CY2016 dei Entity Central Index Key
EntityCentralIndexKey
0001314102
CY2016 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2163000
CY2016 dei Document Period End Date
DocumentPeriodEndDate
2016-06-30
CY2016 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-3808000
CY2016 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.68
CY2016 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-20000
CY2016 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2016 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2163000
CY2016 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2016
CY2016 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2016 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.68
CY2016 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-21640000
CY2016 dei Amendment Flag
AmendmentFlag
false
CY2016 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
-159000
CY2016 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--06-30
CY2016 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2016 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9013000
CY2016 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.68
CY2016 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: medium 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <font style="FONT-FAMILY: 'Times New Roman'" size="2"><b>Concentrations of Risk</b></font></p> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: medium 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6px; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> <font style="FONT-FAMILY: 'Times New Roman'" size="2">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents and marketable securities. At June 30, 2016, $13.0 million, or 93.5% of the Company&#x2019;s interest-bearing cash equivalent balances, were concentrated in one institutional money market fund that has investments consisting primarily of certificates of deposit, commercial paper, time deposits and treasury repurchase agreements. Generally, these deposits may be redeemed upon demand and, therefore, the Company believes they have minimal risk. Marketable securities at June 30, 2016 and 2015 consisted of investment-grade corporate bonds and commercial paper. The Company&#x2019;s investment policy, approved by the Board of Directors, includes guidelines relative to diversification and maturities designed to preserve principal and liquidity.</font></p> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: medium 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> <font style="FONT-FAMILY: 'Times New Roman'" size="2">Revenues from Alimera accounted for $233,000, or 14% of total revenues in fiscal 2016, $25.1 million, or 95% of total revenues in fiscal 2015 and were inconsequential in fiscal 2014. Revenues from Bausch &amp; Lomb accounted for $1.3 million, or 77% of total revenues in fiscal 2016, $1.2 million, or 5% of total revenues in fiscal 2015 and $1.3 million, or 38% of total revenues in fiscal 2014. A completed feasibility study agreement accounted for $1.7 million, or 49%, of total revenues in fiscal 2014.</font></p> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: medium 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> <font style="FONT-FAMILY: 'Times New Roman'" size="2">Accounts receivable from Bausch &amp; Lomb accounted for $288,000, or 59%, of total accounts receivable at June 30, 2016 and $371,000, or 60%, of total accounts receivable at June 30, 2015.</font></p> </div>
CY2016 us-gaap Depreciation
Depreciation
152000
CY2016 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2016 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
756000
CY2016 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2016 us-gaap Employee Service Share Based Compensation Cash Received From Exercise Of Stock Options
EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions
490000
CY2016 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y9M18D
CY2016 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.34 pure
CY2016 us-gaap Revenues
Revenues
1620000
CY2016 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
882000
CY2016 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
485000
CY2016 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
72000
CY2016 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1036000
CY2016 us-gaap Income Taxes Paid
IncomeTaxesPaid
4000
CY2016 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-7379000
CY2016 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
6789000
CY2016 us-gaap Operating Expenses
OperatingExpenses
23394000
CY2016 us-gaap Net Income Loss
NetIncomeLoss
-21547000
CY2016 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
17517000
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-21702000
CY2016 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-4462000
CY2016 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-96000
CY2016 us-gaap License And Services Revenue
LicenseAndServicesRevenue
398000
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-19780000
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-1922000
CY2016 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
626000
CY2016 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-187000
CY2016 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-93000
CY2016 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
0 shares
CY2016 us-gaap Operating Income Loss
OperatingIncomeLoss
-21774000
CY2016 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
16990000
CY2016 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0
CY2016 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
778000
CY2016 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
397000
CY2016 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
103000
CY2016 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
3000
CY2016 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-155000
CY2016 us-gaap Nature Of Operations
NatureOfOperations
<div> <table style="FONT-FAMILY: 'Times New Roman'; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left"><font style="FONT-FAMILY: 'Times New Roman'" size="2"><b>1.</b></font></td> <td valign="top" align="left"><font style="FONT-FAMILY: 'Times New Roman'" size="2"><b>Operations</b></font></td> </tr> </table> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); PADDING-BOTTOM: 0px; FONT: medium 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6px; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> <font style="FONT-FAMILY: 'Times New Roman'" size="2">pSivida Corp. (together with its subsidiaries, the &#x201C;Company&#x201D;), incorporated in Delaware, develops sustained-release drug delivery products primarily for the treatment of chronic eye diseases. The Company&#x2019;s products deliver drugs at a controlled and steady rate for months or years. The Company has developed three of only four sustained-release products approved by the U.S. Food and Drug Administration (&#x201C;FDA&#x201D;) for treatment of back-of-the-eye diseases. Medidur&#x2122; for posterior segment uveitis, the Company&#x2019;s lead product candidate, is in pivotal Phase 3 clinical trials, and ILUVIEN<font style="FONT-FAMILY: 'Times New Roman'" size="1"><sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex">&#xAE;</sup></font>&#xA0;for diabetic macular edema (&#x201C;DME&#x201D;), the Company&#x2019;s lead licensed product, is sold in the U.S. and three European Union (&#x201C;EU&#x201D;) countries. The Company&#x2019;s product development program is focused primarily on utilizing its two core technology platforms to deliver drugs and biologics to treat chronic diseases.&#xA0;Its strategy includes developing products independently while continuing to leverage its technology platforms through collaborations and license agreements as appropriate.</font></p> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: medium 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> <font style="FONT-FAMILY: 'Times New Roman'" size="2">Medidur, the Company&#x2019;s most advanced development product, is designed to treat chronic non-infectious uveitis affecting the posterior segment of the eye (&#x201C;posterior segment uveitis&#x201D;) for three years from a single injection. Injected into the eye in an office visit, Medidur is a tiny micro-insert that delivers a micro-dose of a corticosteroid to the back of the eye on a sustained basis.&#xA0;The Company is developing Medidur independently.</font></p> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: medium 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> <font style="FONT-FAMILY: 'Times New Roman'" size="2">The first of Medidur&#x2019;s two Phase 3 trials met its primary efficacy endpoint of prevention of recurrence of disease through six months with high statistical significance.&#xA0;The same high statistical significance for efficacy and encouraging safety results was maintained through 12 months of follow-up. Due to the high level of statistical significance achieved, the Company plans to file its EU marketing approval application (&#x201C;MAA&#x201D;) based on data from the first Phase 3 trial, rather than two trials. The MAA is planned for the first quarter of 2017. Enrollment in the second Phase 3 trial is expected to be completed in October 2016. Assuming favorable results, the Company plans to file a new drug application (&#x201C;NDA&#x201D;) with the FDA in the third quarter of 2017.&#xA0;A utilization study of the Company&#x2019;s new Medidur inserter with a smaller diameter needle, which is required for both the MAA and NDA, met its primary endpoint, ease of intravitreal administration.</font></p> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); PADDING-BOTTOM: 0px; FONT: medium 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> <font style="FONT-FAMILY: 'Times New Roman'" size="2">ILUVIEN<font style="FONT-FAMILY: 'Times New Roman'" size="1"><sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex">&#xAE;</sup></font>, the Company&#x2019;s most recently approved product, is an injectable, sustained-release micro-insert that provides three years of treatment of DME from a single injection. ILUVIEN is substantially the same design as Medidur and delivers the same steroid, although it is injected using a larger diameter inserter.&#xA0;ILUVIEN was developed in collaboration with, and is licensed to and sold by Alimera Sciences, Inc. (&#x201C;Alimera&#x201D;).&#xA0;The Company is entitled to a share of the net profits (as defined) from Alimera&#x2019;s sales of ILUVIEN on a quarter-by-quarter, country-by-country basis. ILUVIEN has been sold in the United Kingdom (&#x201C;U.K.&#x201D;) and Germany since 2013 and in the U.S. and Portugal since 2015, and also has marketing approvals in 14 other European countries.</font></p> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); PADDING-BOTTOM: 0px; FONT: medium 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> <font style="FONT-FAMILY: 'Times New Roman'" size="2">FDA-approved Retisert<font style="FONT-FAMILY: 'Times New Roman'" size="1"><sup style="VERTICAL-ALIGN: baseline; POSITION: relative; BOTTOM: 0.8ex">&#xAE;</sup></font>&#xA0;is an implant that provides sustained treatment of posterior segment uveitis for 30 months.&#xA0;Implanted in a surgical procedure, Retisert delivers the same corticosteroid as Medidur but in a larger dose.&#xA0;Retisert was co-developed with, and licensed to, Bausch&#xA0;&amp; Lomb, and the Company receives royalties from its sales.</font></p> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: medium 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> <font style="FONT-FAMILY: 'Times New Roman'" size="2">The Company is seeking to develop products that use its Durasert&#x2122; and Tethadur&#x2122; technology platforms to deliver drugs and biologics to treat wet and dry age-related macular degeneration (&#x201C;AMD&#x201D;), glaucoma, osteoarthritis and other diseases.&#xA0;The sustained release, surgical implant to treat pain associated with severe knee osteoarthritis (&#x201C;OA&#x201D;) the Company developed in collaboration with Hospital for Special Surgery is in an investigator-sponsored pilot study.&#xA0;The Company has commenced the first of two investigational new drug (&#x201C;IND&#x201D;)-enabling studies of an injectable, bioerodible micro-insert it developed to provide sustained delivery of a tyrosine kinase inhibitor (&#x201C;TKI&#x201D;) to treat wet AMD.</font></p> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: medium 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0px; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> <font style="FONT-FAMILY: 'Times New Roman'" size="2">The Company has a history of operating losses and has financed its operations primarily from sales of equity securities and the receipt of license fees, milestone payments, research and development funding and royalty income from its collaboration partners. The Company believes that its cash, cash equivalents and marketable securities of $29.0 million at June 30, 2016, together with expected cash inflows under existing collaboration agreements, will enable the Company to maintain its current and planned operations into the second quarter of fiscal year 2018. This estimate excludes any potential receipts under the Alimera collaboration agreement. The Company&#x2019;s ability to fund its planned operations beyond then, including completion of clinical development of Medidur, is expected to depend on the amount and timing of cash receipts from Alimera&#x2019;s commercialization of ILUVIEN, proceeds from any future collaboration or other agreements and/or proceeds from any financing transactions. There is no assurance that the Company will receive significant, if any, revenues from the commercialization of ILUVIEN or financing from any other sources.</font></p> </div>
CY2016 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-16316000
CY2016 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-1044000
CY2016 us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
-116000
CY2016 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
113000
CY2016 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
0
CY2016 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
16500000
CY2016 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0197 pure
CY2016 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Use of Estimates</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the reported amounts and disclosure of assets and liabilities at the date of the consolidated financial statements and the reported amounts and disclosure of revenues and expenses during the reporting periods. Significant management estimates and assumptions include, among others, those related to revenue recognition for multiple-deliverable arrangements, recognition of expense in outsourced clinical trial agreements, recoverability of intangible assets, realization of deferred tax assets and the valuation of stock option awards. Actual results could differ from these estimates.</p> </div>
CY2016 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
31623473 shares
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.80 pure
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000 pure
CY2016 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
16500000
CY2016 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
31623473 shares
CY2016 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
490000
CY2016 dei Trading Symbol
TradingSymbol
PSDV
CY2016 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14381000
CY2016 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
490000
CY2015Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29412000 shares
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
967000
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0147 pure
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.74
CY2016 us-gaap Share Based Compensation
ShareBasedCompensation
2163000
CY2016 us-gaap Royalty Revenue
RoyaltyRevenue
1222000
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.76 pure
CY2016 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
31623000 shares
CY2016 psdv Proceeds From Maturity Of Marketable Securities
ProceedsFromMaturityOfMarketableSecurities
13168000
CY2016 psdv Income Tax Reconciliation Capital Loss Expirations
IncomeTaxReconciliationCapitalLossExpirations
0
CY2016 psdv Warrants Outstanding Remaining Contractual Life
WarrantsOutstandingRemainingContractualLife
P1Y1M6D
CY2016 psdv Defined Contribution Plan Contributions By Employer
DefinedContributionPlanContributionsByEmployer
209000
CY2016 psdv Defined Contribution Plans Employee Contribution Percentage Of Eligible Compensation Matched By Employer
DefinedContributionPlansEmployeeContributionPercentageOfEligibleCompensationMatchedByEmployer
0.05 pure
CY2016 psdv Income Tax Reconciliation Expiration Of State Net Operating Loss Carry Forwards
IncomeTaxReconciliationExpirationOfStateNetOperatingLossCarryForwards
0
CY2016 psdv Warrants To Purchase Common Shares Expired
WarrantsToPurchaseCommonSharesExpired
552500 shares
CY2016 psdv Incremental Common Shares Attributable To Warrants
IncrementalCommonSharesAttributableToWarrants
0 shares
CY2016 psdv Income Tax Reconciliation Permanent Items
IncomeTaxReconciliationPermanentItems
216000
CY2016 psdv Exercise Price Of Expired Warrants
ExercisePriceOfExpiredWarrants
5.00
CY2016 psdv Marketable Securities Weighted Average Maturity
MarketableSecuritiesWeightedAverageMaturity
P3M
CY2016 psdv Increase Decrease In Deferred Rent
IncreaseDecreaseInDeferredRent
5000
CY2015Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.17
CY2015Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.17
CY2015Q1 us-gaap Revenues
Revenues
328000
CY2015Q1 us-gaap Net Income Loss
NetIncomeLoss
-4998000
CY2015Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-5052000
CY2015Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
29412000 shares
CY2016Q2 us-gaap Net Income Loss
NetIncomeLoss
-6387000
CY2016Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-6456000
CY2016Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
34152000 shares
CY2014Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.14
CY2014Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.14
CY2014Q4 us-gaap Revenues
Revenues
521000
CY2014Q4 us-gaap Net Income Loss
NetIncomeLoss
-4075000
CY2014Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-4116000
CY2016Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.15
CY2016Q1 us-gaap Revenues
Revenues
324000
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-5041000
CY2016Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-5096000
CY2016Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
33538000 shares
CY2015Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.17
CY2015Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.17
CY2015Q2 us-gaap Revenues
Revenues
409000
CY2015Q2 us-gaap Net Income Loss
NetIncomeLoss
-5146000
CY2015Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-5200000
CY2015Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
29412000 shares
CY2015Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29412000 shares
CY2016Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.19
CY2016Q2 us-gaap Revenues
Revenues
304000
CY2014Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
29367000 shares
CY2014Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29367000 shares
CY2015Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.17
CY2015Q3 us-gaap Revenues
Revenues
466000
CY2015Q3 us-gaap Net Income Loss
NetIncomeLoss
-4933000
CY2015Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-4984000
CY2015Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
29416000 shares
CY2015Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.18
CY2015Q4 us-gaap Revenues
Revenues
526000
CY2015Q4 us-gaap Net Income Loss
NetIncomeLoss
-5186000
CY2015Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-5238000
CY2015Q4 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
29437000 shares
CY2014Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.70
CY2014Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.67
CY2014Q3 us-gaap Revenues
Revenues
25307000
CY2014Q3 us-gaap Net Income Loss
NetIncomeLoss
20566000
CY2014Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
20789000
CY2014Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
30765000 shares
CY2014Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29323000 shares

Files In Submission

Name View Source Status
0001193125-16-708358-index-headers.html Edgar Link pending
0001193125-16-708358-index.html Edgar Link pending
0001193125-16-708358.txt Edgar Link pending
0001193125-16-708358-xbrl.zip Edgar Link pending
d222569d10k.htm Edgar Link pending
d222569dex211.htm Edgar Link pending
d222569dex231.htm Edgar Link pending
d222569dex311.htm Edgar Link pending
d222569dex312.htm Edgar Link pending
d222569dex321.htm Edgar Link pending
d222569dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
psdv-20160630.xml Edgar Link completed
psdv-20160630.xsd Edgar Link pending
psdv-20160630_cal.xml Edgar Link unprocessable
psdv-20160630_def.xml Edgar Link unprocessable
psdv-20160630_lab.xml Edgar Link unprocessable
psdv-20160630_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending